Chris MÃ¼hlhausen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7427859/publications.pdf

Version: 2024-02-01

20	1,917	567281 15	752698 20
papers	citations	h-index	g-index

20	20	20	2592
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lysine Glutarylation Is a Protein Posttranslational Modification Regulated by SIRT5. Cell Metabolism, 2014, 19, 605-617.	16.2	647
2	Diagnosis and management of glutaric aciduria type I â€“ revised recommendations. Journal of Inherited Metabolic Disease, 2011, 34, 677-694.	3.6	327
3	Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. Journal of Inherited Metabolic Disease, 2017, 40, 75-101.	3.6	173
4	Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. Journal of Neurochemistry, 2006, 97, 899-910.	3.9	147
5	Use of guidelines improves the neurological outcome in glutaric aciduria type I. Annals of Neurology, 2010, 68, 743-752.	5.3	147
6	Decline of Acute Encephalopathic Crises in Children with Glutaryl-CoA Dehydrogenase Deficiency Identified by Newborn Screening in Germany. Pediatric Research, 2007, 62, 357-363.	2.3	102
7	Bi-allelic Truncating Mutations in TANGO2 Cause Infancy-Onset Recurrent Metabolic Crises with Encephalocardiomyopathy. American Journal of Human Genetics, 2016, 98, 358-362.	6.2	77
8	Newborn screening: A diseaseâ€changing intervention for glutaric aciduria type 1. Annals of Neurology, 2018, 83, 970-979.	5.3	65
9	Disease-Linked Glutarylation Impairs Function and Interactions of Mitochondrial Proteins and Contributes to Mitochondrial Heterogeneity. Cell Reports, 2018, 24, 2946-2956.	6.4	42
10	Combined D2â€/L2â€hydroxyglutaric aciduria (SLC25A1 deficiency): clinical course and effects of citrate treatment. Journal of Inherited Metabolic Disease, 2014, 37, 775-781.	3.6	32
11	Transport and distribution of 3-hydroxyglutaric acid before and during induced encephalopathic crises in a mouse model of glutaric aciduria type 1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 385-390.	3.8	29
12	Behavioural and emotional problems, intellectual impairment and healthâ€related quality of life in patients with organic acidurias and urea cycle disorders. Journal of Inherited Metabolic Disease, 2016, 39, 231-241.	3.6	29
13	Interaction of Glutaric Aciduria Type 1-Related glutaryl-CoA Dehydrogenase with Mitochondrial Matrix Proteins. PLoS ONE, 2014, 9, e87715.	2.5	20
14	Living with Intoxication-Type Inborn Errors of Metabolism: A Qualitative Analysis of Interviews with Paediatric Patients and Their Parents. JIMD Reports, 2016, 31, 1-9.	1.5	20
15	Development and Psychometric Evaluation of the MetabQoL 1.0: A Quality of Life Questionnaire for Paediatric Patients with Intoxication-Type Inborn Errors of Metabolism. JIMD Reports, 2017, 37, 27-35.	1.5	15
16	Disease-causing mutations affecting surface residues of mitochondrial glutaryl-CoA dehydrogenase impair stability, heteromeric complex formation and mitochondria architecture. Human Molecular Genetics, 2017, 26, ddw411.	2.9	14
17	Glutaric Aciduria Type 1 and Acute Renal Failure: Case Report and Suggested Pathomechanisms. JIMD Reports, 2017, 39, 25-30.	1.5	12
18	Mannose phosphate isomerase deficiencyâ€congenital disorder of glycosylation (MPIâ€CDG) with cerebral venous sinus thrombosis as first and only presenting symptom: A rare but treatable cause of thrombophilia. JIMD Reports, 2020, 55, 38-43.	1.5	8

#	Article	IF	Citations
19	Ammonium accumulation and chemokine decrease in culture media of Gcdhâˆ’/âˆ’ 3D reaggregated brain cell cultures. Molecular Genetics and Metabolism, 2019, 126, 416-428.	1.1	6
20	Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies. Expert Review of Neurotherapeutics, 2021, 21, 1275-1282.	2.8	5